Suppr超能文献

血液透析患者的抗凝风险。

The risk of anticoagulation in hemodialysis patients.

作者信息

Biggers J A, Remmers A R, Glassford D M, Sarles H E, Lindley J D, Fish J C

出版信息

Nephron. 1977;18(2):109-13. doi: 10.1159/000180784.

Abstract

The risks of intermittent anticoagulation with heparin for hemodialysis and longterm anticoagulation with warfarin to prevent clotting of arteriovenous shunts were assessed in a group of 125 home dialysis patients. Over a 7-year period, there were nine bleeding complications attributable to heparin anticoagulation for an incidence of one complication for every 40 patient year on dialysis. In contrast, 20 of 48 patients anticoagulated with warfarin for an average of 2 years each, had a total of 50 hemorrhagic complications requiring 542 days in the hospital and 15 operative procedures. Concersion to an alternative form of vascular access, the internal arteriovenous fistula, obviated the need for warfarin therapy and its unacceptably high complication rate in this population of patients.

摘要

在一组125例家庭透析患者中,评估了肝素用于血液透析间歇性抗凝以及华法林用于长期抗凝以预防动静脉分流器凝血的风险。在7年期间,有9例出血并发症归因于肝素抗凝,透析患者每年每40例出现1例并发症。相比之下,48例接受华法林抗凝的患者平均每人抗凝2年,共有50例出血并发症,住院时间达542天,接受了15次手术。改用另一种血管通路形式,即动静脉内瘘,消除了该患者群体对华法林治疗的需求及其高得令人无法接受的并发症发生率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验